Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026)
Celldex Therapeutics (CLDX) recorded quarterly EBT Margin of 524566.67% in Q1 2026, down 680.56% quarter-over-quarter from 67204.13% in Q4 2025, and down 51682624.0% on a YoY basis from N/an in Q1 2025.
Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 524566.67% for Q1 2026.
- In Q1 2026, EBT Margin fell 51682624.0% year-over-year to 524566.67%; the TTM figure through Mar 2026 stood at 32753.58% (down 3038751.0% YoY), while the FY2025 annual figure was 16748.03%, down 1449927.0% from the prior year.
- EBT Margin was 524566.67% for Q1 2026 at Celldex Therapeutics, down from 67204.13% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 1048.32% in Q4 2023 to a low of 524566.67% in Q1 2026.
- Historically, EBT Margin has averaged 43537.78% across 5 years, with a median of 7160.63% in 2022.
- The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 1329034 bps in 2025, then sank 51682624 bps in 2026.
- A 5-year view of EBT Margin shows it stood at 1642.1% in 2022, then surged by 36 bps to 1048.32% in 2023, then plunged by 282 bps to 4007.83% in 2024, then tumbled by 1577 bps to 67204.13% in 2025, then sank by 681 bps to 524566.67% in 2026.
- The last three EBT Margin figures came in at 524566.67% (Q1 2026), 67204.13% (Q4 2025), and 7753.42% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Celldex Therapeutics | 2.16 Bn | 2.16 Bn | -1.44 Mn | -524,566.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -524,566.67% |
| Dec 31, 2025 | -67,204.13% |
| Jun 30, 2025 | -7,753.42% |
| Mar 31, 2025 | -7,740.43% |
| Dec 31, 2024 | -4,007.83% |
| Sep 30, 2024 | -1,319.99% |
| Jun 30, 2024 | -1,434.83% |
| Mar 31, 2024 | -21,030.77% |
| Dec 31, 2023 | -1,048.32% |
| Sep 30, 2023 | -2,522.08% |
| Jun 30, 2023 | -11,381.34% |
| Mar 31, 2023 | -3,036.30% |
| Dec 31, 2022 | -1,642.10% |
| Sep 30, 2022 | -6,580.84% |
| Jun 30, 2022 | -22,088.34% |
| Mar 31, 2022 | -13,247.13% |
| Dec 31, 2021 | -6,032.34% |
| Sep 30, 2021 | -13,515.69% |
| Jun 30, 2021 | -384.28% |
| Mar 31, 2021 | -2,414.31% |